39.585 USD
-0.13 (-0.34%)
RPRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. RPRX scores excellent on profitability, but there are some minor concerns on its financial health. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
- RPRX had positive earnings in the past year.
- RPRX had a positive operating cash flow in the past year.
- RPRX had positive earnings in each of the past 5 years.
- Each year in the past 5 years RPRX had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of RPRX (3.95%) is better than 84.74% of its industry peers.
- The Return On Equity of RPRX (11.93%) is better than 86.32% of its industry peers.
- RPRX's Return On Invested Capital of 6.43% is amongst the best of the industry. RPRX outperforms 84.21% of its industry peers.
- RPRX had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 12.84%.
- The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
- With an excellent Profit Margin value of 32.55%, RPRX belongs to the best of the industry, outperforming 95.26% of the companies in the same industry.
- RPRX's Profit Margin has declined in the last couple of years.
- The Operating Margin of RPRX (65.22%) is better than 100.00% of its industry peers.
- RPRX's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RPRX is destroying value.
- RPRX has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for RPRX has been increased compared to 5 years ago.
- The debt/assets ratio for RPRX is higher compared to a year ago.
2.2 Solvency
- RPRX has an Altman-Z score of 1.70. This is a bad value and indicates that RPRX is not financially healthy and even has some risk of bankruptcy.
- RPRX has a Altman-Z score of 1.70. This is comparable to the rest of the industry: RPRX outperforms 56.84% of its industry peers.
- The Debt to FCF ratio of RPRX is 9.47, which is on the high side as it means it would take RPRX, 9.47 years of fcf income to pay off all of its debts.
- RPRX's Debt to FCF ratio of 9.47 is fine compared to the rest of the industry. RPRX outperforms 79.47% of its industry peers.
- RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
- RPRX's Debt to Equity ratio of 1.34 is on the low side compared to the rest of the industry. RPRX is outperformed by 76.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.7 |
ROIC/WACC0.75
WACC8.57%
2.3 Liquidity
- RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of RPRX (3.48) is comparable to the rest of the industry.
- A Quick Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
- With a Quick ratio value of 3.48, RPRX perfoms like the industry average, outperforming 57.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
- RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.24%.
- The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
- Looking at the last year, RPRX shows a small growth in Revenue. The Revenue has grown by 3.70% in the last year.
- The Revenue has been growing slightly by 4.52% on average over the past years.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
- Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.53% on average per year.
- The Revenue is expected to grow by 10.65% on average over the next years. This is quite good.
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.65%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.63, the valuation of RPRX can be described as reasonable.
- RPRX's Price/Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 91.05% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.54, RPRX is valued rather cheaply.
- The Price/Forward Earnings ratio is 7.64, which indicates a rather cheap valuation of RPRX.
- Based on the Price/Forward Earnings ratio, RPRX is valued cheaply inside the industry as 91.58% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.31, RPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.63 | ||
| Fwd PE | 7.64 |
4.2 Price Multiples
- RPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RPRX is cheaper than 83.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.19 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- RPRX has a very decent profitability rating, which may justify a higher PE ratio.
- RPRX's earnings are expected to grow with 13.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y12.38%
EPS Next 3Y13.48%
5. Dividend
5.1 Amount
- RPRX has a Yearly Dividend Yield of 2.19%. Purely for dividend investing, there may be better candidates out there.
- RPRX's Dividend Yield is rather good when compared to the industry average which is at 0.35. RPRX pays more dividend than 94.21% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.92, RPRX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.19% |
5.2 History
- RPRX has been paying a dividend for over 5 years, so it has already some track record.
- RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
NASDAQ:RPRX (1/16/2026, 10:36:49 AM)
39.585
-0.13 (-0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners81.5%
Inst Owner Change0.13%
Ins Owners1.56%
Ins Owner Change7.63%
Market Cap22.85B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts84.29
Price Target46.34 (17.06%)
Short Float %7.15%
Short Ratio6.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.19% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)0.74%
PT rev (3m)4.57%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)2.06%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)4.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.2%
Revenue NY rev (1m)0.39%
Revenue NY rev (3m)1.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.63 | ||
| Fwd PE | 7.64 | ||
| P/S | 9.72 | ||
| P/FCF | 24.19 | ||
| P/OCF | 9.5 | ||
| P/B | 3.56 | ||
| P/tB | 4.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.38%
EPS(NY)5.18
Fwd EY13.08%
FCF(TTM)1.64
FCFY4.13%
OCF(TTM)4.17
OCFY10.53%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.56
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.7 |
F-Score5
WACC8.57%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.65%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.71%
EBIT Next 3Y14.53%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.63 and the Price/Book (PB) ratio is 3.56.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.